|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification Number)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
Item 5.07 |
Submission of Matters to a Vote of Security Holders.
|
1. |
The proposal to adopt and approve the Merger Agreement (the “Merger Agreement Proposal”):
|
Votes For
|
|
Votes Against
|
|
Votes Abstained
|
32,912,387
|
|
238,713
|
|
6,318
|
2. |
The proposal to approve, on an advisory (non-binding) basis, the compensation that will or may be paid or become payable to the Company’s named executive officers that is based
on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement (the “Compensation Proposal”):
|
Votes For
|
|
Votes Against
|
|
Votes Abstained
|
18,380,470
|
|
14,706,202
|
|
70,746
|
3. |
The proposal to approve the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, including to solicit additional proxies to approve the
Merger Agreement Proposal if there are insufficient votes to approve the Merger Agreement Proposal at the time of the Special Meeting (the “Adjournment
Proposal”):
|
Votes For
|
|
Votes Against
|
|
Votes Abstained
|
31,215,947
|
|
1,918,300
|
|
23,171
|
AERIE PHARMACEUTICALS, INC.
|
||
Date: November 18, 2022
|
By:
|
/s/ Peter Lang
|
Name: Peter Lang
|
||
Title: Chief Financial Officer
|
Document and Entity Information |
Nov. 17, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Nov. 17, 2022 |
Entity File Number | 001-36152 |
Entity Registrant Name | Aerie Pharmaceuticals, Inc. |
Entity Central Index Key | 0001337553 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 20-3109565 |
Entity Address, Address Line One | 4301 Emperor Boulevard |
Entity Address, Address Line Two | Suite 400 |
Entity Address, City or Town | Durham |
Entity Address, State or Province | NC |
Entity Address, Postal Zip Code | 27703 |
City Area Code | 919 |
Local Phone Number | 237-5300 |
Title of 12(b) Security | Common Stock, par value $0.001 per share |
Trading Symbol | AERI |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
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